News

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...
Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...
How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...
Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...
Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...
HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...
The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.
Relevance (G.F. Fleming) Capecitabine plus an aromatase inhibitor can be considered in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who do not tolerate a CDK 4,6 ...
I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want ...